Miyashita Taishi, Senshu Masanori, Ibi Kanata, Yamanaka Hiroyuki, Nejishima Hiroaki, Fukami Tatsuki, Nakajima Miki
Pharmacokinetics and Safety Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 301, Gensuke, Fujieda, Shizuoka 426-8646, Japan; Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.
Pharmacokinetics and Safety Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 301, Gensuke, Fujieda, Shizuoka 426-8646, Japan.
Toxicology. 2022 Jan 15;465:153064. doi: 10.1016/j.tox.2021.153064. Epub 2021 Dec 8.
Drug-induced lens opacity has the potential to cause blindness and is of concern in drug development. Inhibition of cholesterol biosynthesis is one of the causes of lens opacity. Lens opacity is only observed after chronic administration in in vivo nonclinical studies in drug development. Thus, to save resources (e.g., time and cost) and to reduce burden on animals, it is required to develop in vitro evaluation systems that can predict and avoid the risk of lens opacity earlier and easier. In this study, we investigated whether rat lens explant cultures could be useful for the evaluation of drug-induced lens opacity via inhibition of cholesterol biosynthesis. Nineteen drugs, including statins, allylamine, thiocarbamate, azole, and morpholine, which inhibit cholesterol biosynthesis, as well as a negative control (acetaminophen, rosiglitazone and troglitazone), were used. Rat lens explants were treated with drugs for 13 days at concentrations close to IC values or higher against cholesterol biosynthesis, and lens opacity (severity and region) was evaluated. In most cases, region-specific lens opacity limited in the equator to posterior pole, as observed in vivo was observed at IC values or higher concentrations. The severity of opacity was likely to be related to the inhibitory potency toward cholesterol biosynthesis, concentration of drugs distributed in the lens, or time of exposure. Furthermore, GSH levels were also involved in the deterioration of lens opacity. In conclusion, we demonstrated that rat lens explant cultures can be useful to assess the potential drug-induced lens opacity associated with inhibition of cholesterol biosynthesis and to elucidate the mechanisms of lens opacity.
药物性晶状体混浊有可能导致失明,在药物研发中备受关注。抑制胆固醇生物合成是晶状体混浊的原因之一。在药物研发的体内非临床研究中,仅在长期给药后才会观察到晶状体混浊。因此,为了节省资源(如时间和成本)并减轻动物负担,需要开发能够更早、更轻松地预测和避免晶状体混浊风险的体外评估系统。在本研究中,我们调查了大鼠晶状体外植体培养物是否可用于通过抑制胆固醇生物合成来评估药物性晶状体混浊。使用了19种抑制胆固醇生物合成的药物,包括他汀类药物、烯丙胺、硫代氨基甲酸盐、唑类和吗啉类,以及阴性对照(对乙酰氨基酚、罗格列酮和曲格列酮)。将大鼠晶状体外植体用药物以接近或高于对胆固醇生物合成的IC值的浓度处理13天,并评估晶状体混浊(严重程度和区域)。在大多数情况下,在IC值或更高浓度下观察到了如在体内所观察到的那样局限于赤道至后极的区域特异性晶状体混浊。混浊的严重程度可能与对胆固醇生物合成的抑制效力、晶状体中分布的药物浓度或暴露时间有关。此外,谷胱甘肽水平也与晶状体混浊的恶化有关。总之,我们证明了大鼠晶状体外植体培养物可用于评估与抑制胆固醇生物合成相关的潜在药物性晶状体混浊,并阐明晶状体混浊的机制。